All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a healthcare professional. If you are a patient or carer, please visit the MPN Advocates Network.
The MPN Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the MPN Hub cannot guarantee the accuracy of translated content. The MPN Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The MPN Hub is an independent medical education platform, sponsored by AOP Health, GSK, and Novartis, and supported through educational grants from Blueprint Medicines, Incyte, and Bristol Myers Squibb. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View MPN content recommended for you
How to diagnose ISM
Do you know... Which of the following findings helps to distinguish ISM from more advanced subtypes of SM?
Systemic mastocytosis (SM) is a rare mast-cell neoplasm that can be difficult to recognize and is frequently underdiagnosed or misclassified in clinical practice.1 Advances in targeted therapies for SM have increased the importance of accurate diagnosis and disease classification for guiding clinical management.1 Indolent systemic mastocytosis (ISM) is the most common subtype of SM, accounting for ~70–80% of cases in adults.1 Here, we outline the latest diagnostic criteria for SM and highlight the diagnostic findings and key morphologic features that distinguish ISM from other subtypes.
This educational resource is independently supported by Blueprint Medicines. All content was developed by SES in collaboration with an expert steering committee. Funders were allowed no influence.
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
